To conclude, the data presented in the current study demonstrate that the presence of naive and effector CD4+ Treg are clearly correlated with poor clinical outcome, while high expression of terminal effector cells correlates with better clinical outcome in patients with metastatic NSCLC. The gene discussed is CD4; the disease is non-small cell lung carcinoma.